<![CDATA[LintonPharm Co. Ltd. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=35521>Sat, 02 May 2026 10:42:37 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[LintonPharm Announces Authorization from China Health Authority (NMPA) to Proceed with a Phase 1/2 Trial Evaluating Catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer]]>https://www.newswire.co.kr/newsRead.php?no=921553Wed, 14 Apr 2021 15:30:00 +0900<![CDATA[린톤팜, 중국 국가약품감독관리국이 비근침습성 방광암 환자 치료 위해 카투막소맙을 평가하는 1/2상 임상시험 진행 승인했다고 발표]]>https://www.newswire.co.kr/newsRead.php?no=921554Wed, 14 Apr 2021 15:30:00 +0900<![CDATA[LintonPharm Announces Authorization From China Health Authority to Proceed With a Global Phase 3 Trial Evaluating Catumaxomab in Advanced Gastric Cancer]]>https://www.newswire.co.kr/newsRead.php?no=907998Fri, 17 Jul 2020 11:40:00 +0900<![CDATA[린톤팜, 중국 약품관리국으로부터 진행성 위암에 대한 카투막소맙의 효능 평가하는 글로벌 3상 임상시험 승인 획득]]>https://www.newswire.co.kr/newsRead.php?no=908000Fri, 17 Jul 2020 11:40:00 +0900